Home/Pipeline/MK-0616

MK-0616

Hypercholesterolemia

Phase 3Active, Ongoing

Key Facts

Indication

Hypercholesterolemia

Phase

Phase 3

Status

Active, Ongoing

Company

Merck

About Merck

Merck & Co. is a research-intensive biopharmaceutical giant with a foundational mission to put medicine before profits, driving global health impact. Its strategic focus is on high-growth therapeutic areas, most notably oncology led by blockbuster KEYTRUDA, complemented by a robust vaccine portfolio and promising pipeline. The company leverages a multi-modal technology platform and significant financial strength to sustain innovation, navigate patent cliffs, and pursue strategic business development to fuel long-term growth.

View full company profile

Therapeutic Areas

Oncology Vaccines Immunology Cardiometabolic Infectious Diseases Neuroscience

Other Hypercholesterolemia Drugs

Drug	Company	Phase	Status
VXX-401	Vaxxinity	Phase 1	Active
Atorvastatin Oral Liquid Suspension	CMP Pharma	Approved	Marketed
AFFITOPE® AT04 (licensed to Frontier Biotech)	AFFiRiS	Phase 1	Active
AQR-008	Aqur Biosciences	Pre-clinical	Active
Leqvio® (inclisiran)	Novartis	Approved	Active
SHR-1209	Jiangsu Hengrui Medicine	Phase III	Active
IBI-306	Innovent Biologics	NDA Submitted	Active
Inusiran (AK102)	Akeso	Approved	Commercial
Obicetrapib + Ezetimibe FDC	NewAmsterdam Pharma Company	Phase 3	Completed (TANDEM)